Currently, the company sits on a 27-acre lot, and manufactures drugs at its 127,000-sf plant in a quantity only large enough for testing purposes. With the new facility, Human Genome Sciences will produce novel human hormones and proteins, as well as human antibody drugs. "We appreciate the strong support of the financial community which has enabled Human Genome Sciences to finance this important expansion," says company Senior Vice President Steven C. Mayer.
Gilbane Building Company is leading the construction effort and expects to complete the 360,000-sf development half way through 2003. Just four months ago, Human Genome Sciences began construction on another structure, which will be nearly 420,000-sf in size.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
